PT - JOURNAL ARTICLE AU - Kayoko Shioda AU - Max SY Lau AU - Alicia NM Kraay AU - Kristin N Nelson AU - Aaron J Siegler AU - Patrick S Sullivan AU - Matthew H Collins AU - Joshua S Weitz AU - Benjamin A Lopman TI - Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies AID - 10.1101/2020.11.13.20231266 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.13.20231266 4099 - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231266.short 4100 - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231266.full AB - Background Serology tests can identify previous infections and facilitate estimation of the number of total infections. However, immunoglobulins targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported to wane below the detectable level of serological assays. We estimate the cumulative incidence of SARS-CoV-2 infection from serology studies, accounting for expected levels of antibody acquisition (seroconversion) and waning (seroreversion), and apply this framework using data from New York City (NYC) and Connecticut.Methods We estimated time from seroconversion to seroreversion and infection fatality ratio (IFR) using mortality data from March-October 2020 and population-level cross-sectional seroprevalence data from April-August 2020 in NYC and Connecticut. We then estimated the daily seroprevalence and cumulative incidence of SARS-CoV-2 infection.Findings The estimated average time from seroconversion to seroreversion was 3-4 months. The estimated IFR was 1.1% (95% credible interval: 1.0-1.2%) in NYC and 1.4% (1.1-1.7%) in Connecticut. The estimated daily seroprevalence declined after a peak in the spring. The estimated cumulative incidence reached 26.8% (24.2-29.7%) and 8.8% (7.1-11.3%) at the end of September in NYC and Connecticut, higher than maximum seroprevalence measures (22.1% and 6.1%), respectively.Interpretation The cumulative incidence of SARS-CoV-2 infection is underestimated using cross-sectional serology data without adjustment for waning antibodies. Our approach can help quantify the magnitude of underestimation and adjust estimates for waning antibodies.Funding This study was supported by the US National Science Foundation and the National Institute of Allergy and Infectious Diseases.Competing Interest StatementBAL reports personal fees from Takeda Pharmaceutical, personal fees from CDC Foundation, and personal fees from Hall Booth Smith, P.C., outside the submitted work. Other authors do not have conflicts of interest.Funding StatementThis study was supported by the US National Science Foundation [grant 2032082 to JSW and grant 2032084 to BAL] and the US National Institute of Allergy and Infectious Diseases [3R01AI143875-02S1 to PSS and AJS].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Georgia Department of Public Health Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used publicly available, deidentified, aggregate data downloaded from the government websites cited in the paper.